GH secretagogue

CJC-1295 (no DAC)

Also known as Mod GRF 1-29

Amplifies natural GH pulses, almost always paired with Ipamorelin.

Clinical evidence

Overview

CJC-1295 (no DAC), also called Mod GRF 1-29, is a growth hormone-releasing hormone analog designed to amplify the size of each natural GH pulse without disrupting the rhythm your body already uses. Unlike the version with a drug affinity complex, this form has a short active window - which is why it is almost always paired with a GHRP like ipamorelin rather than used on its own. The main goals it serves are building lean muscle, supporting recovery, and aiding fat loss, with longevity as a secondary benefit. It is commonly prescribed to people doing active training who want to optimize body composition without flattening their natural GH pattern. CJC-1295 (no DAC) is given as a subcutaneous injection, typically before bed and/or after a workout on an empty stomach. The standard dose is 100 mcg, and it can be taken one to three times daily depending on the protocol. Courses typically run three to six months before reassessment. The main practical caution is that it should be taken on an empty stomach - food and elevated insulin blunt the pulse. Because it works on the GH axis, it carries the same cancer-history contraindication as other GH secretagogues. It is compounded in the US and frequently dispensed already blended with ipamorelin, which simplifies the injection routine. CJC-1295 (no DAC) should not be combined with MK-677 or with the DAC version of CJC-1295. It pairs well with ipamorelin. Your licensed provider in the PepDepo network will determine the exact protocol that fits your goals at consult.

At a glance

Route

SC injection

Dose

100 mcg

Frequency

1-3x daily

Timing

Before bed and/or post-workout, empty stomach

Cycle

3-6 months

Combining

Stacks well with: Ipamorelin

Avoid combining with: MK-677 (Ibutamoren)

Safety

Best on an empty stomach to avoid blunting the pulse.

Regulatory: Compounded; often dispensed blended with Ipamorelin.

Not appropriate if: cancer-history.

Questions

What is the difference between CJC-1295 with and without DAC?⌄

The no-DAC version has a short active window and preserves your natural pulsatile GH rhythm. The DAC version stays active for days and raises your GH baseline more continuously. They are used differently and should not be combined.

Why is CJC-1295 (no DAC) almost always paired with ipamorelin?⌄

CJC-1295 (no DAC) amplifies the size of a GH pulse - it increases the amplitude. Ipamorelin triggers the pulse itself. Together they give a stronger and more complete GH release than either does alone.

How is it taken?⌄

As a subcutaneous injection at 100 mcg, one to three times daily depending on protocol. Timing is before bed and/or after a workout, on an empty stomach.

Why does it need to be taken on an empty stomach?⌄

Elevated blood sugar and insulin blunt the GH pulse that CJC-1295 (no DAC) is designed to amplify. An empty stomach gives the signal a cleaner window to work.

Who should not use this peptide?⌄

Anyone with a cancer history should not use CJC-1295 (no DAC). GH-axis stimulation is contraindicated in that setting.

How long does a course last?⌄

Three to six months is the typical course length, after which a clinician reassesses. The exact duration depends on your goals and response.

Where does my exact dose get set?⌄

At your PepDepo consult. The 100 mcg figure here is educational context. Your clinician sets the personalized protocol based on your health history and goals.

Related protocols

Recomp

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.